The only & only BOTOX® Cosmetic

BOTOX® Cosmetic is FDA approved for the temporary improvement of the appearance of moderate to severe platysma bands, forehead lines, lateral canthal lines, and glabellar lines in adults.1

Partner with Allergan Aesthetics

Real BOTOX® Cosmetic patient.
Treated for the appearance of moderate to severe platysma bands. Results may vary.

Experience BOTOX® Cosmetic.

All botulinum toxins are unique2

Botulinum toxins, like BOTOX® Cosmetic, are biologics—inherently unique, derived from living organisms, and sensitive to manufacturing differences.2

Why BOTOX® Cosmetic

The first of its kind to be approved3

BOTOX® Cosmetic has been FDA approved for over 20 years.3

Clinical studies

Real Patient. Results may vary.

The most studied product of its kind4

BOTOX® Cosmetic is the most studied neurotoxin, with over 6600 publications that feature BOTOX® (onabotulinumtoxinA) and/or BOTOX® Cosmetic.4,*

Science

*For therapeutic and aesthetic use.4

FDA approved to treat
4 areas

BOTOX® Cosmetic is the first and only neurotoxin FDA approved for moderate to severe platysma bands, forehead lines, lateral canthal lines, and glabellar lines.1,5-9

BOTOX® COSMETIC AUTHENTICITY

Is your BOTOX® Cosmetic authentic and FDA approved
for use in the US? 

Here’s how to be sure.

Learn More

The one & only
BOTOX® Cosmetic.

BOTOX® Cosmetic is FDA approved for
the appearance of moderate to severe
platysma bands, forehead lines, lateral
canthal lines, and glabellar lines in adults.
See real patient results.1

Forehead, glabellar, lateral canthal lines
Platysma bands

Real patient before treatment.

Discover the science
behind the most
studied neurotoxin.4,*

See the science

Charles Boyd, MD, MBA, FACS

“I choose BOTOX® Cosmetic because it was the first product of its kind to be approved and it’s trusted.”1,12-14,†,‡,§

[Embeddable: vimeo]

John Fezza, MD

“I choose BOTOX® Cosmetic because I have been injecting it since it came out 20 years ago.”1,12,†

[Embeddable: vimeo]

Kim Nichols, MD, FAAD

“I choose BOTOX® Cosmetic because it is studied, it provides predictable results, and it’s been on the market for over 20 years.”1,4,12,*,†

[Embeddable: vimeo]

Nicola Lowery, MPAP,
PA-C

“I choose BOTOX® Cosmetic because
of the first-class BOTOX® Cosmetic training I
receive with Allergan Medical Institute®.”

[Embeddable: vimeo]

*As of July 2025, BOTOX® (onabotulinumtoxinA) and BOTOX® Cosmetic have been studied in over 6600 peer-reviewed publications for therapeutic and aesthetic use, more than any other neurotoxin.4
†In April 2002, BOTOX® Cosmetic became the first product of its kind to receive FDA approval to treat moderate to severe glabellar lines in adults.3
‡Based on a 2023 online survey of 251 neurotoxin patients. When asked which of the attributes they associate with BOTOX® Cosmetic, 83% (n = 233) stated that it “Is a brand I trust.”10
§Based on a 2023 online survey of 241 specialists. When asked how important specific attributes were when they are deciding which neurotoxin to carry, 83% of specialists rated “Is a brand I trust” as important. Additionally, 49% (n = 236) of specialists selected “Is a brand I trust” as an attribute associated with BOTOX® Cosmetic.11

The one with the most neurotoxin experience and a one-of-a-kind formulation.1,5-9

30+ years of experience ensuring quality product.1, 17

AbbVie owns end-to-end development from drug substance development to manufacturing and distribution.17

Most studied neurotoxin based on peer-reviewed publications.4

Over 6600 publications featuring BOTOX® or BOTOX® Cosmetic.4,*

*For therapeutic and aesthetic use.

More FDA approvals than any other neurotoxin.1,5-9,18

4 BOTOX® Cosmetic aesthetic uses and 12 BOTOX® therapeutic uses.1,18

The one with a history of aesthetic firsts.

1989

BOTOX® (onabotulinumtoxinA) becomes the first neurotoxin approved for therapeutic use.8

2002

BOTOX® Cosmetic becomes the first neurotoxin approved for aesthetic use for moderate to severe glabellar lines.1,5-9,12

2009

Allergan creates the first aesthetic patient loyalty program—now known as Allē.*

*Launched in 2009 as Brilliant Distinctions®.

2011

BOTOX® and BOTOX® Cosmetic introduce the first-of-its-kind cell-based assay, reducing the need for animal testing.3,7,11-16

2014

BOTOX® Cosmetic is the first neurotoxin to be approved for moderate to severe lateral canthal lines.1,3,5-9,12

2017

BOTOX® Cosmetic is the first
neurotoxin to be approved for moderate to severe forehead lines—making it
the first neurotoxin to be approved
for treatment in
3 areas.1,3,5-9,12,18

2019

BOTOX® celebrates 30 years since initial approval.18

2022

BOTOX® Cosmetic celebrates 20 years since initial approval.3

2023

Celebrating the fifth year of BOTOX® Cosmetic Day.

2024

BOTOX® Cosmetic is the first and only neurotoxin FDA approved to temporarily improve the appearance of moderate to severe platysma bands.1,5-9

Get Started

Allergan Medical Institute®

Level up your skills and learn to administer Allergan Aesthetics products.

Learn more

Real BOTOX® Cosmetic patient.

Treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.

Allergan Direct®

Purchase products, pay bills, and access detailed reports at your convenience.

Learn more

Discover how Allergan Aesthetics can power your journey as a provider.

When you become a customer, you get access to our entire family of brands, plus resources, tools, and medical education to support you and your practice.

Allē Rewards

Allē Members spend 4x the amount on facial injectables versus the general aesthetic consumer.20,*

Learn More

*Based on an online survey of 1937 Allē members and 2043 US aesthetic consumers who spent on a neurotoxin treatment in the past year.

Allē 

Simplifying the business of aesthetics.

Learn More

Allergan Medical Institute®

Level up your skills and learn to administer Allergan Aesthetics products.

Learn More

BOTOX® Cosmetic IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

BOTOX® Cosmetic (onabotulinumtoxinA) Important Information

Indications

BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:

- Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity

- Moderate to severe lateral canthal lines associated with orbicularis oculi activity

- Moderate to severe forehead lines associated with frontalis activity

- Moderate to severe platysma bands associated with platysma muscle activity


BOTOX® Cosmetic IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

CONTRAINDICATIONS

BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

WARNINGS AND PRECAUTIONS
Lack of Equivalency Between Botulinum Toxin Products
The potency Units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. BOTOX® Cosmetic is not equivalent to other preparations of botulinum toxin products, and therefore, Units of biological activity of BOTOX® Cosmetic cannot be compared to nor converted into Units of any other botulinum toxin products assessed with any other specific assay method.

Spread of Toxin Effect
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported. Patients or caregivers should be advised to seek immediate medical care if swallowing, speech, or respiratory disorders occur.

Serious Adverse Reactions With Unapproved Use

Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX® injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX® to the site of injection and/or adjacent structures. In several of the cases, patients had preexisting dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX®. The safety and effectiveness of BOTOX® for unapproved uses have not been established.

Hypersensitivity Reactions

Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such a reaction occurs, discontinue further injection of BOTOX® Cosmetic and immediately institute appropriate medical therapy. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

Cardiovascular System

There have been reports following administration of BOTOX® of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors, including preexisting cardiovascular disease. Use caution when administering to patients with preexisting cardiovascular disease.

Increased Risk of Clinically Significant Effects With Preexisting Neuromuscular Disorders

Patients with neuromuscular disorders may be at increased risk of clinically significant effects, including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see Warnings and Precautions). Monitor individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) when given botulinum toxin.

Dysphagia and Breathing Difficulties

Treatment with BOTOX® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with preexisting swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see Boxed Warning). 

Preexisting Conditions at the Injection Site

Use caution when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s). 

Dry Eye in Patients Treated With BOTOX® Cosmetic

There have been reports of dry eye associated with BOTOX® Cosmetic injection in or near the orbicularis oculi muscle. If symptoms of dry eye (eg, eye irritation, photophobia, or visual changes) persist, consider referring patients to an ophthalmologist.

Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries a remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), which would also be considered remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

ADVERSE REACTIONS

The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for glabellar lines were eyelid ptosis (3%), facial pain (1%), facial paresis (1%), and muscular weakness (1%).


The most frequently reported adverse reaction following injection of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%).


The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for forehead lines with glabellar lines were headache (9%), brow ptosis (2%), and eyelid ptosis (2%).


The safety profile of BOTOX® Cosmetic treatment of platysma bands is consistent with the known safety profile of BOTOX® Cosmetic for other indications.



DRUG INTERACTIONS

Coadministration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX® Cosmetic may potentiate systemic anticholinergic effects.


The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.


Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX® Cosmetic.


USE IN SPECIFIC POPULATIONS

There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX® Cosmetic in pregnant women. There are no data on the presence of BOTOX® Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk production.


Please see BOTOX® Cosmetic full Prescribing Information, including Boxed Warning and Medication Guide.

BOTOX® Cosmetic (onabotulinumtoxinA) Important Information

Indications

BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:

- Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity

- Moderate to severe lateral canthal lines associated with orbicularis oculi activity

- Moderate to severe forehead lines associated with frontalis activity

- Moderate to severe platysma bands associated with platysma muscle activity


BOTOX® Cosmetic IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

CONTRAINDICATIONS

BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

WARNINGS AND PRECAUTIONS
Lack of Equivalency Between Botulinum Toxin Products
The potency Units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. BOTOX® Cosmetic is not equivalent to other preparations of botulinum toxin products, and therefore, Units of biological activity of BOTOX® Cosmetic cannot be compared to nor converted into Units of any other botulinum toxin products assessed with any other specific assay method.

Spread of Toxin Effect
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported. Patients or caregivers should be advised to seek immediate medical care if swallowing, speech, or respiratory disorders occur.

Serious Adverse Reactions With Unapproved Use

Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX® injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX® to the site of injection and/or adjacent structures. In several of the cases, patients had preexisting dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX®. The safety and effectiveness of BOTOX® for unapproved uses have not been established.

Hypersensitivity Reactions

Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such a reaction occurs, discontinue further injection of BOTOX® Cosmetic and immediately institute appropriate medical therapy. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

Cardiovascular System

There have been reports following administration of BOTOX® of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors, including preexisting cardiovascular disease. Use caution when administering to patients with preexisting cardiovascular disease.

Increased Risk of Clinically Significant Effects With Preexisting Neuromuscular Disorders

Patients with neuromuscular disorders may be at increased risk of clinically significant effects, including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see Warnings and Precautions). Monitor individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) when given botulinum toxin.

Dysphagia and Breathing Difficulties

Treatment with BOTOX® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with preexisting swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see Boxed Warning). 

Preexisting Conditions at the Injection Site

Use caution when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s). 

Dry Eye in Patients Treated With BOTOX® Cosmetic

There have been reports of dry eye associated with BOTOX® Cosmetic injection in or near the orbicularis oculi muscle. If symptoms of dry eye (eg, eye irritation, photophobia, or visual changes) persist, consider referring patients to an ophthalmologist.

Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries a remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), which would also be considered remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

ADVERSE REACTIONS

The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for glabellar lines were eyelid ptosis (3%), facial pain (1%), facial paresis (1%), and muscular weakness (1%).


The most frequently reported adverse reaction following injection of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%).


The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for forehead lines with glabellar lines were headache (9%), brow ptosis (2%), and eyelid ptosis (2%).


The safety profile of BOTOX® Cosmetic treatment of platysma bands is consistent with the known safety profile of BOTOX® Cosmetic for other indications.



DRUG INTERACTIONS

Coadministration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX® Cosmetic may potentiate systemic anticholinergic effects.


The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.


Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX® Cosmetic.


USE IN SPECIFIC POPULATIONS

There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX® Cosmetic in pregnant women. There are no data on the presence of BOTOX® Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk production.


Please see BOTOX® Cosmetic full Prescribing Information, including Boxed Warning and Medication Guide.

References: 1. BOTOX® Cosmetic Prescribing Information, October 2024. 2. Daller J. Biosimilars: a consideration of the regulations in the United States and European Union. Regul Toxicol Pharmacol. 2016;76:199-208. 3. BOTOX® Cosmetic (onabotulinumtoxinA) celebrates 20 years since first U.S. FDA approval. News release. AbbVie. April 13, 2022. Accessed May 27, 2025. https://news.abbvie.com/2022-04-13-BOTOX-R-Cosmetic-onabotulinumtoxinA-Celebrates-20-Years-Since-First-U-S-FDA-Approval. 4. Data on file, Allergan Aesthetics, July 2025; Botulinum Toxin Peer-Reviewed Publications. 5. Dysport Prescribing Information, September 2023. 6. Xeomin Prescribing Information, July 2024. 7. Jeuveau Prescribing Information, April 2023. 8. Daxxify Prescribing Information, November 2023. 9. Letybo Prescribing Information, February 2024. 10. Data on file, Allergan Aesthetics, December 2024; NTX Consumer A&U. 11. Data on file, Allergan Aesthetics, December 20, 2023; HCP NTX A&U. 12. Data on file, Allergan, April 12, 2002; Botulinum Toxin Type A. Product Approval Information: Licensing Action. 13. Data on file, Allergan Aesthetics, January 2022; HCP Facial NTX ATU. 14. Data on file, Allergan Aesthetics, July 2018; BOTOX® Cosmetic Module (UN11). 15. Ogilvie P, Rivkin AZ, Dayan S, et al. Pooled subject-reported outcomes from 2 phase 3 studies of onabotulinumtoxinA for simultaneous treatment of forehead and glabellar lines. Dermatol Surg. 2020;46:950-957. 16. Data on file, Allergan Aesthetics, February 14, 2023; Consumer NTX A&U. 17. Data on file, Allergan Aesthetics, October 29, 2020; Westport Manufacturing Process. 18. BOTOX® Prescribing Information, November 2023. 19. Pellett S. Progress in cell based assays for botulinum neurotoxin detection. Curr Top Microbiol Immunol. 2013;364:257-285. 20. Data on file, Allergan, February 16, 2024; Allē Market Sizing Summary Report.

AbbVie may use and disclose online usage data about you collected automatically through online tracking technologies such as cookies, pixels, and web beacons (collectively, “cookies”). We use this data for multiple purposes, including for online targeted advertising (advertisements